e-Therapeutics Plc (ETX.L) posted loss attributable to equity holders of the company of 3.24 million pounds for the year ended January 31, 2012 compared to the loss of 2.31 million pounds last year. Meanwhile, loss per share narrowed to 2.47 pence from 3.51 pence in the prior year.
Pre-tax loss widened to 3.86 million pounds from 2.66 million pounds in the previous year.
The company did not record any revenues for the year.
e-Therapeutics' CFO, Dr Daniel Elger, said, "Our 2012 results reflect increasing investment in drug discovery and drug development made possible by shareholders' support of a significant capital raise during the year. We are confident that continuing this investment will yield promising new drugs and advance our pipeline towards value-realising partnering deals."
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.